Previous Article | Next Article 
Journal of Virology, February 1999, p. 1286-1292, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Epstein-Barr Virus Promotes Epithelial Cell Growth
in the Absence of EBNA2 and LMP1 Expression
Jun
Nishikawa,1,2
Shosuke
Imai,2
Takanori
Oda,2
Toshichika
Kojima,3
Kiwamu
Okita,1 and
Kenzo
Takada2,*
First Department of Internal Medicine,
Yamaguchi University School of Medicine, Ube
755-8505,1
Department of Virology,
Cancer Institute, Hokkaido University School of Medicine, Sapporo
060-8638,2 and
Department of
Gastroenterology, Jichi Medical School, Minamikawachi
329-0400,3 Japan
Received 31 August 1998/Accepted 19 October 1998
 |
ABSTRACT |
We attempted to infect primary gastric epithelia (PGE) with
recombinant Epstein-Barr virus (EBV) carrying a selectable marker that
made it possible to select EBV-infected cells. Cells dually positive
for EBV-determined nuclear antigen (EBNA) and cytokeratin were detected
in 3 of 21 primary cultures after 3 days of EBV inoculation. From one
culture, EBV-infected cell clones were repeatedly obtained at a
frequency of 3 to 5 cell clones per 106 cells. EBV-infected
clones had enhanced population doubling and grew to attain a highly
increased saturation density, together with acquisition of marked
anchorage independence. The infected clones retained the
ultrastructural morphology characteristic of gastric mucosal epithelium
and have been growing stably for more than 18 months (corresponding to
at least 300 generations) so far, in clear contrast to the parental PGE
cells, which ceased growth after 60 generations. The p53 gene of the
parental PGE cells was found to be overexpressed, perhaps thereby
conferring the basal potential for long-term survival in vitro.
Moreover, EBV infection accelerated, to a significant extent, the
growth rate and agar clonability of NU-GC-3 cells, an established
EBV-negative but EBV-susceptible human gastric carcinoma cell line.
Both EBV-converted PGE and NU-GC-3 clones, like EBV-positive gastric
carcinoma biopsy specimens, expressed a restricted set of EBV latent
infection genes characterized by the absence of EBNA2 and latent
membrane protein 1 (LMP1) expression. These results indicate that EBV
infection causes a transformed phenotype on PGE in the setting of
possible unregulated cell cycling and renders even established gastric carcinoma cells more malignant via a limited spectrum of viral latent-gene expression. This study may reflect an in vivo scenario illustrating multiphasic involvement of EBV in carcinogenesis of
gastric or other epithelial cancers.
 |
INTRODUCTION |
Epstein-Barr virus (EBV) is a
ubiquitous virus which infects the majority of the human population and
is the causative agent of infectious mononucleosis (27).
Recently, increasing evidence has linked EBV infection to various
epithelioid malignancies as well as lymphoid ones. The very strong
association between EBV and nasopharyngeal carcinoma (NPC) is already
well known (27). Moreover, the viral genome is detected in
rare carcinomas with intense lymphoid stroma (termed
lymphoepithelioma-like carcinoma) arising in the salivary glands
(29), thymus (6), and stomach (33). In
addition, an increasing number of studies have suggested a causal
relationship between EBV and primary gastric carcinoma of the more
common adenocarcinoma type (11, 33). About 5 to 15%
patients with gastric carcinoma in all parts of the world have EBV DNA
in 100% of carcinoma cells (11, 13, 18, 30, 34). Analysis
of the terminal sequence of EBV plasmid DNA in gastric carcinoma cells
indicated that tumor cells arose from a single EBV-infected cell, thus
suggesting that EBV infection had occurred in the very early stage of
tumor development (13). Gastric carcinoma cells express a
limited number of EBV genomes, similar to those in Burkitt's lymphoma,
which are EBV-determined nuclear antigen 1 (EBNA1), two small
nonpolyadenylated RNAs known as EBER1 and EBER2, the transcripts from
the BamHI-A region (BARF0), and latent membrane protein 2A
(LMP2A) (13, 37). This is different from the pattern in NPC,
in which LMP1 is also expressed in carcinoma cells in about half of the
patients (27, 47). Concerning the effects of EBV products on
epithelial cells, LMP1 has some pleiotropic biological activities but
other gene products do not. LMP1 induces epidermal hyperplasia in
transgenic mice (41), alters keratin gene expression in
human keratinocytes (7), inhibits cell differentiation in
some immortalized epithelial cell lines (5), induces
expression of the epidermal growth factor receptor (21), and
blocks p53-mediated apoptosis through activation of the A20 gene
(8). Thus far, there has been no evidence that EBV provides
a continuing contribution to the growth phenotype of EBV-positive
gastric carcinoma, which is negative for LMP1 expression.
Although the interaction between EBV and lymphoid cells has been
studied extensively, the remarkable resistance of epithelial cells to
EBV infection in vitro has hampered studies of the role of EBV in
epithelial malignancies. Recently, we generated EBV recombinants with a
selectable marker, which makes it possible to select EBV-infected cells
even when the efficiency of infection is low or the EBV-uninfected
population in culture is able to proliferate (34, 45). Using
the recombinant virus, we found that various carcinoma cell lines can
be infected with EBV (14, 44) and that their virus
convertants consistently express a limited number of EBV latent genes,
as EBV-positive gastric carcinoma cells do (14), thus
indicating that the system could be a model for EBV oncogenesis. The
present study focused mainly on the effect of EBV infection on primary
gastric epithelial cells by applying our infection system and
demonstrated that EBV promotes epithelial cell growth in the absence of
EBNA2 and LMP1 expression.
 |
MATERIALS AND METHODS |
Culture of primary gastric epithelia.
Primary gastric
epithelia (PGE) were prepared from endoscopically collected or
surgically resected gastric specimens from noncancerous patients. The
tissues were transferred to cold Hanks' balanced salt solution, minced
with blades, and treated at 37°C for 30 min with a mixture of
collagenase type I (100 U/ml; GIBCO BRL, Rockville, Md.), hyaluronidase
type IV-S (0.05%; Sigma, St. Louis, Mo.) and dispase (2 U/ml; GIBCO
BRL) in Hanks' balanced salt solution. The suspension was pipetted
several times to completely disperse PGE during incubation and then
passed through a mesh. The filtrate was washed twice with DM201 culture
medium (Wako Pure Chemical Industries, Osaka, Japan) containing 10%
fetal calf serum (FCS) (GIBCO BRL), penicillin (100 U/ml), streptomycin
(100 µg/ml), and gentamicin (100 µg/ml). The cells were resuspended in the same medium and seeded into six-well culture plates. Cells adhered to the wells within the following 2 days and slowly grew as a
monolayer with small islands. The adherent cells in these cultures were
of epithelial origin morphologically and were positive for cytokeratins
by immunofluorescence staining.
EBV infection and transfection of PGE cells.
Recombinant EBV
of the Akata strain (rEBV) carrying the neomycin resistance gene
(Neor) was used as a source of virus for infection
(35, 43). Implanted PGE cells were exposed to rEBV through
cell-free infection as previously described (14, 44). Two
days after virus inoculation, the cells were reseeded into 24-well
culture plates at 5 × 104 cells/ml/well in a medium
containing G418 (200 µg/ml; GIBCO BRL) for selection. The
Neor gene (pcDNA3 vector; Invitrogen, Carlsbad, Calif.) was
transfected by using the Lipofectamine Plus reagent (GIBCO BRL), and
then the cells were subjected to G418 selection as described above.
Immunofluorescence assay.
Expression of EBNA was examined on
acetone-methanol-fixed cells by anticomplement immunofluorescence with
reference human serum (titer, 1,280). Expression of EBNA2 and LMP1 was
tested on acetone-methanol-fixed cells by streptavidin-biotin
immunofluorescence with mouse monoclonal antibodies (MAbs) PE2
(46) (a gift of E. Kieff, Harvard Medical School, Boston,
Mass.) and CS1-4 (Dako, Glastrup, Denmark), respectively. EBV lytic
infection was assessed on acetone-fixed cells by indirect
immunofluorescence with MAb C1 (39) (a gift of D. A. Thorley-Lawson, Tufts University, Boston, Mass.), specific to the viral
envelope antigen, gp350, and MAb R3 (25) (a gift of G. Pearson, Georgetown University, Washington, D.C.), reactive to the
viral early protein encoded by BMRF1. Cytokeratins were stained with a
mixture of MAbs AE1 and AE3 (Dako) by indirect immunofluorescence.
To examine the expression of the EBV receptor, CD21, cells were
prepared by treatment with 2 mM EDTA-phosphate-buffered saline (pH
7.2) at 37°C for 10 to 15 min, washed with cooled culture medium, and
reacted with MAbs OKB7 (Ortho Diagnostics, Raritan, N.J.) and HB-5
(Becton Dickson, San Jose, Calif.) at 4°C for 30 min. The second
reaction involved the use of a fluorescein isothiocyanate-labeled F(ab')2 fragment of rabbit antibody to mouse immunoglobulin
G (Dako) followed by flow cytometric analysis.
Southern blot analysis.
Purified cellular DNA (5 µg) was
digested with BamHI, size fractionated by electrophoresis in
a 0.7% agarose gel, and transferred to a nylon membrane (Hybond N+;
Amersham International plc, Little Chalfont, United Kingdom). Probe DNA
was labeled with [
-32P]dCTP (3,000 Ci/ml) by random
priming. To detect the EBV genome, the BamHI-K probe was
used. The 1.9-kb XhoI-a subfragment from BamHI-Net and the EcoRI-I and BamHI-C
fragments were also used as probes to investigate EBV integration into
the cellular DNA, which has occasionally been reported to occur at the
termini or within the BamHI-C region of the genome (12,
19, 26). Hybridization was performed at 42°C overnight in 50%
formamide-5× Denhardt's solution-5× SSC (1× SSC is 0.15 M NaCl
plus 0.015 M sodium citrate)-0.5% sodium dodecyl sulfate (SDS)
containing salmon testis DNA (100 µg/ml; Sigma). The blot was washed
twice in 2× SSC-0.1% SDS for 10 min at room temperature and once in
0.1× SSC-0.1% SDS for 10 min at 65°C and then exposed to X-ray
film at
80°C for 15 h.
Morphological characterization.
Phase-contrast micrographs
of cultured cells were obtained with an inverted microscope. For
ultrastructural studies, cells were grown in culture chamber slides
(Becton Dickinson), fixed in 2.5% glutaraldehyde, and postfixed in 1%
osmium tetroxide. Fixed cells were stained with 1% uranyl acetate, and
the slides were examined with an electron microscope.
Immunoblotting.
Cells were lysed in SDS-polyacrylamide gel
electrophoresis loading buffer, sonicated, and boiled for 5 min. A
volume of lysate equal to 105 cells was separated in 10%
polyacrylamide gels and transferred to a nitrocellulose membrane. After
overnight blocking with 5% nonfat dry milk in Tris-buffered saline
(TBS-M [pH 7.6]), the membrane was incubated for 2 h at room
temperature with human sera optimally diluted (1:50 to 1:200) in TBS-M
to detect EBNAs, washed three times with TBS-M containing 0.1% Tween
20 (TBS-TM), and then reacted for 30 min with horseradish
peroxidase-conjugated sheep antibodies to human immunoglobulin G
(diluted 1:2,000 in TBS-M [Amersham]). Expression of EBNA2 and LMP1
was examined by using MAbs PE2 and CS14, and antibody reaction and
washing were done in TBS and TBS-T solutions, respectively. After the
second antibody reaction, the filters were washed five times with
TBS-T, immersed in the enhanced chemiluminescence solutions (Amersham) as specified by the manufacturer, and subjected to autoradiography. We
also examined cytokeratin and p53 expression by immunoblotting with a
mixture of MAbs AE1 and AE3 (Dako) and rabbit polyclonal antibody CM1
(Novocastra Laboratories, Newcastle, United Kingdom), respectively.
Cell lysates from B lymphoblastoid cell lines (LCL) immortalized by the
Akata or B95-8 strain of EBV were used as EBV-positive controls.
In situ hybridization.
In situ hybridization was
performed to investigate EBV-encoded small RNA 1 (EBER1) expression
(40). To do so, 104 cells detached by trypsin
treatment were dispensed into wells of an eight-chamber slide glass
(Nunc-InterMed, Tokyo, Japan) and incubated until the cultures reached
60 to 80% confluence. Then the slides were air dried and fixed with
freshly prepared 4% paraformaldehyde-0.1 M phosphate buffer (pH 7.4)
overnight at 4°C. After being briefly washed with 0.1 M phosphate
buffer, the cells were treated with proteinase K (10 to 30 µg/ml) for 20 min at 37°C, rinsed again in 0.1 M phosphate buffer, and
dehydrated in a 70 to 100% ethanol series. Details of the
hybridization procedures and probe sequence are described elsewhere
(14).
RT-PCR.
Reverse transcription-PCR (RT-PCR) analysis was
carried out to investigate the expression of LMP2A, LMP2B, and BARF0
and the utilization of EBNA promoters (promoters in BamHI-C,
BamHI-W, and BamHI-Q; Cp, Wp, and Qp,
respectively). Total cellular RNA was isolated by guanidium
isothiocyanate-phenol extraction with TRIzol reagent (GIBCO BRL) as
specified by the manufacturer. Extracted RNA was heated for 5 min at
90°C and rapidly cooled on ice. cDNA synthesis was performed for 60 min at 37°C with Moloney murine leukemia virus RTase (GIBCO BRL),
using 100 pmol of random hexamer (Takara, Otsu, Japan) followed by 10 min of heating at 94°C to inactivate RTase. The cDNA samples were
then subjected to 30 cycles of PCR in a thermal cycler. Each cycle
consisted of denaturation for 30 s at 94°C, annealing for
30 s at 45 to 55°C, and extension for 1 min at 72°C. The
reaction mixture contained buffers and reagents as described previously
(37), with 20 pmol of each primer and cDNA (equivalent to 5 × 104 cells/tube) in a volume of 50 µl. A 5-µl samples of
the PCR products was electrophoresed on a 2% agarose gel and blotted
onto nylon membranes, and specific amplified DNA was detected with a
32P-end-labeled oligoprobe. Details of primer and probe
sequences are described in our previous reports (14, 37).
RNAs from LCL and Akata cells (38) were used as positive
controls. The quality of the RNA was checked by parallel amplification
of
-actin mRNA.
Analysis of cell growth and tumorigenicity in mice.
The
population-doubling time and saturation (maximal) cell density were
determined by seeding the same number of viable cells into wells of
12-well culture plates (2 ml of medium) or 6-well culture plates (5 ml
of medium) and counting the number of cells in each well every day for
10 days. Growth curves in liquid culture were obtained at standard and
low serum concentrations. Anchorage-independent growth ability was
assessed by plating cells in six-well culture plates at variable cell
numbers (from 0.25 × 104 to 5 × 104
viable cells) suspended in DM201 medium-0.4% agarose (SeaPlaque; Takara) containing 20% FCS as a triplicate culture for each cell number. They were incubated at 37°C under 5% CO2 for 4 weeks. Tumorigenicity was tested by inoculating 107 cells
subcutaneously into athymic nude mice and SCID mice (female, BALB/c
background), which were subsequently observed for progressive tumor
formation for 12 weeks.
DNA sequencing.
Exons 5 to 8 of the p53 gene were PCR
amplified with fluorescently labeled dideoxy chain-terminating
nucleotides (Thermo Sequenase Dye terminator cycle-sequencing premix
kit; Amersham) basically as specified by the supplier. Primers for PCR
and direct sequencing were based on published sequence (32).
PCR products were purified and analyzed on an automated DNA sequencer
(model 373; Applied Biosystems Inc., Foster City, Calif.).
 |
RESULTS |
EBV infection of primary gastric epithelial cells.
We could
obtain a sufficient number of cells for infection experiments from 21 independent PGE cultures. Successful EBV infection was discerned in
three of these cultures by coexpression of EBNA and cytokeratins (up to
0.2%), and the following selection culture produced several
G418-resistant clones from a single PGE culture (referred to as PGE-5).
In the other primary cultures, cells became extinct by 10 days after
addition of G418 to the medium or ceased to grow within 1 month even in
the absence of G418. The drug-resistant PGE-5 cells have been growing
stably for more than 18 months (corresponding to at least 300 generations) so far, with weekly subcultivation by diluting them 1:10.
All of the G418-resistant PGE-5 clones showed virtually 100%
positivity for EBNA by immunofluorescence assay (Fig.
1A and 1B). EBV infection of the
resistant clones was confirmed by Southern hybridization with an EBV
BamHI-K probe (Fig. 1C). In each EBV-carrying clone,
hybridization of BamHI-digested DNA with the
XhoI-a probe detected a single terminal fragment band, and
rehybridization of the same blots with the EcoRI-I probe also detected a single band identical in size to that detected by the
XhoI-a probe (data not shown). The BamHI-C probe
identified the standard BamHI-C fragment in all clones
tested. These results signified that EBV is maintained in the
G418-resistant PGE-5 clones as an episomal form, not integrated into
the cellular DNA. Unexpectedly, parental PGE-5 cells could be
propagated, although slowly, for a certain period; they became extinct
after 30 passages (the life span was approximately 60 generations).
EBV-infected, G418-resistant cell clones were reproducibly obtained
from the PGE-5 culture of passages 5 through 8 at the frequency of 3 to
5 cell clones per 106 initial cells.

View larger version (91K):
[in this window]
[in a new window]
|
FIG. 1.
Detection of EBV in G418-resistant PGE-5 clones. (A)
Immunofluorescent staining of EBNA in a G418-resistant PGE-5 clone with
EBV-seropositive human serum. Magnification, ×400. (B)
Immunofluorescent staining in the same PGE-5 clone with
EBV-seronegative human serum as a control. Magnification, ×400. (C)
Southern blot analysis of G418-resistant PGE-5 clones. All DNA samples
were digested with BamHI, and the blot was probed with a
BamHI-K fragment of EBV DNA. Serially diluted Raji cell DNAs
served as positive controls. Each lane of PGE-5 clones and parental
PGE-5 cells contained 5 µg of DNA. All G418-resistant PGE-5 clones
were estimated to carry more than 25 copies of the EBV genome per
cell.
|
|
Immunofluorescence analysis showed cytokeratin expression in 100% of
the cells. Western blot analysis also confirmed cytokeratin
expression
(Fig.
2A). Electron microscopic
observation demonstrated
that PGE-5 cells had junctional complexes
(tight junctions and
desmosomes) and many electron-dense mucus granules
(Fig.
2B and
C). These findings provided conclusive evidence for the
gastric
mucosal epithelium origin of PGE-5 cells. Parental PGE-5 cells
of passages 5 through 8 previously stored at

152°C were thawed
and
transfected with a Neo
r gene, thereby providing a total of
six Neo
r-carrying clones (neo-PGE-5), which served as a
control for the
following analyses.

View larger version (125K):
[in this window]
[in a new window]
|
FIG. 2.
Demonstration of the epithelial nature of PGE-5 cells.
(A) Immunoblot analysis for cytokeratin expression in EBV-infected and
-uninfected PGE-5 cells. A mixture of MAbs AE1 and AE3 detected
cytokeratins as multisized specific bands between 40 and 66 kDa. A
gastric carcinoma cell line, NU-GC-3, served as a positive control, and
LCL served as a negative control. (B and C) Transmission electron
micrographs of EBV-infected PGE-5 cells show the junctional complex
(arrows) (B) and mucus granules (arrows) (C). Bars in panels B and C
denote 200 nm and 1 µm, respectively. Magnifications, ×8,000 (B) and
×20,000 (C).
|
|
We could not detect the expression of CD21 in PGE-5 cells by
flow-cytometric analysis with anti-CD21 MAbs (OKB7 and HB-5)
or by
sensitive RT-PCR (data not shown). Moreover, addition of
MAb OKB7,
which recognizes and blocks the EBV-binding site on
the CD21 molecule,
to the culture did not reduce the incidence
of emergence of
EBV-infected PGE clones. These results were compatible
with our
previous data indicating that direct EBV infection of
epithelial cells
could be mediated by a novel epithelium-specific
binding receptor for
EBV (
14,
44).
EBV gene expression in PGE-5 clones.
PGE-5 clones infected
with rEBV were examined for the expression of EBV genes. All
EBV-infected clones were positive for EBNA1 but negative for the other
EBNAs and LMP1 in immunoblot (Fig. 3A)
and immunofluorescence assays (data not shown). In situ hybridization studies showed that EBER1 expression was observed specifically in the
nuclei of all cells of each EBV-infected PGE-5 clone (Fig. 3B). RT-PCR
analysis revealed that infected clones used exclusively Qp, not Cp or
Wp, for EBNA1 transcription (Fig. 3C), confirming that a restricted
program of latency is maintained in these cells (22, 31).
The expression of LMP1, LMP2A, LMP2B, and BARF0 was further examined by
RT-PCR, which showed that EBV-infected PGE-5 clones expressed LMP2A and
BARF0 but not LMP1 or LMP2B (Fig. 3C). EBV replicative
antigen-expressing cells were rarely seen (<0.1%) in virus-infected
clones. Taken together, these results indicated that the viral latency
in EBV-infected PGE-5 clones was similar to that typically observed in
EBV-associated gastric carcinoma cells (13, 37) and
LMP1-negative NPC cells (47).

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of EBV latent-gene expression in EBV-infected
PGE-5 cell clones. (A) Immunoblotting for detection of EBNAs and LMP1.
The blots were probed with pooled human sera for EBNA1, EBNA2, EBNA3A,
EBNA3B, and EBNA3C (top blot), MAb PE2 for EBNA2 (middle blot), and MAb
CS1-4 for LMP1 (bottom blot). Protein samples extracted from
105 cells were loaded per slot. (B) In situ hybridization
for EBER1. An EBV-infected PGE-5 clone was hybridized with the
antisense oligoprobe (left) and with the sense oligoprobe (right).
Intense nuclear signals are evident only with the antisense probe. (C)
RT-PCR analysis of EBV latent-gene expression and EBNA promoter usage
in EBV-infected clones. Akata cells were used as a positive control for
detection of Qp-initiated EBNA mRNA, and LCL was used as a positive
control for detection of LMP1, LMP2A, LMP2B, and BARF0 mRNAs and Cp- or
Wp-initiated EBNA mRNAs. Parental PGE-5 cells served as a negative
control.
|
|
Morphological and growth characteristics of EBV-infected PGE
cells.
Morphologically, individual cells of neo-PGE-5 clones as
well as EBV-uninfected parent PGE-5 had a so-called cobblestone shape, as a population, they showed a pavement-like growth appearance (Fig.
4A). EBV-infected PGE-5 cells, on the
other hand, had bipolar spindle-shaped morphology at the single-cell
level. They were highly condensed, with a seemingly parallel
orientation to each other, near to the saturation phase (Fig. 4B).
Furthermore, when their growth kinetics were compared, EBV conversion
clearly gave rise to enhanced population doubling with higher maximum
confluence (Fig. 4B and C). The doubling time and maximal cell density
of each cell group cultured in 2 ml of 10% FCS-containing medium in
12-well plates were estimated to be 85 h and 4.5 × 105 cells/well for neo-PGE-5 clones and 50 h and
9.2 × 105 cells/well for EBV-infected PGE-5 clones.
These values for neo-PGE-5 and EBV-infected PGE-5 clones were
calculated as an average of the results from four clones. A reduction
of the concentration of FCS in the medium to 0.1% still allowed
EBV-infected clones to grow with a slightly prolonged doubling time of
70 h and a lower saturation density of 7.2 × 105
cells/well, whereas Neor-transfected clones could not
proliferate (Fig. 4C). In agreement with the results of fluid culture,
a striking difference in clonability in semisolid agar was also found
between neo-PGE-5 and EBV-infected PGE-5 clones (Table
1). In the soft-agarose assay, neo-PGE-5 clones formed only small colonies (each comprising less than 20 cells)
during the first 2 weeks; however, most of them stopped growing
thereafter and finally died by 3 weeks after seeding (Fig. 5A). In sharp contrast, EBV-infected
clones continuously grew and finally formed large colonies by 3 weeks
after seeding (Fig. 5B). Two of three EBV-infected clones examined
transiently produced subcutaneous tumors in SCID mice (10 to 15 mm in
diameter) around 6 weeks postinoculation, although the tumors regressed
after 10 weeks. PGE-5 cells and neo-PGE-5 clones did not form tumors in SCID mice. None of them was tumorigenic in nude mice, irrespective of
EBV infection.

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 4.
Growth characteristics of Neor-transfected
and EBV-infected PGE-5 clones. (A) Neor-transfected PGE-5
clone. Magnification, ×100. (B) EBV-infected PGE-5 clone.
Magnification, ×100. Both clones were detached by trypsinization,
seeded into separate wells of 12-well plates under the same culture
conditions, and photographed at near the plateau phase (5 days after
passage). Differences between the two cell types are easily
recognizable (see the text for details). (C) Growth kinetics of
EBV-infected (solid circles) and Neor-transfected (open
circles) PGE-5 cells at normal and low FCS concentrations. Individual
data are plotted as a circle with a vertical bar, which represents the
mean ± standard error calculated from the results of four
clones.
|
|

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 5.
Growth in soft agarose of EBV-infected PGE-5 clones and
controls. (A) Neor-transfected PGE-5 clone as a control.
Magnification, ×40. (B) EBV-infected PGE-5 clone. Magnification, ×40.
A total of 104 cells at the logarithmic phase were seeded
per well in six-well plates. The number of viable colonies was counted
and photographed 4 weeks after seeding. Almost all colonies in the
control culture consisted of dead cells, whereas the virus-infected
clone formed many large colonies.
|
|
Overexpression of the p53 gene in EBV-infected and -uninfected
PGE-5 cells.
To investigate the possibility that a cellular gene
confers intrinsic growth potential on parental PGE-5 cells, which is
represented by their prolonged survival in vitro, we analyzed the
expression of a tumor suppressor gene, p53. Immunoblot analysis clearly
showed that p53 accumulated not only in all EBV-infected clones but
also in parental PGE-5 cells (Fig. 6). On
the other hand, p53 was not detected in other two PGE cultures.
Subsequent nucleotide sequencing of exons 5 to 8 of the p53 gene by the
PCR-based method failed to identify mutations or deletions in PGE-5
cells but detected a single nucleotide mutation in intron 5.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
Immunoblot analysis of p53 expression in EBV-infected
and -uninfected PGE-5 cells. The gastric carcinoma cell line NU-GC-3
was used as a positive control for p53 overexpression. PGE-17 and
PGE-21 denote other PGE lysates.
|
|
Growth alteration of a gastric carcinoma cell line by EBV
infection.
We further investigated whether EBV endows an already
established carcinoma cell line with more malignant phenotypes. Of the various human epithelial cell lines that we previously succeeded in
infecting with EBV in vitro, an EBV-negative gastric carcinoma cell
line, NU-GC-3 (1), was used for this purpose. EBV-converted NU-GC-3 clones displayed, as already reported (14), the same program of viral gene expression as EBV-associated gastric carcinoma cells and EBV-infected PGE-5 cells in the present study (Fig. 7A). In medium containing 10% FCS, the
growth rate and saturation density of EBV-infected NU-GC-3 clones
(population doubling time, 24 h; maximal cell density, 5.0 × 106 cells/well [Fig. 7B]) distinctly differed from those
of Neor-transfected NU-GC-3 clones (population doubling
time, 38 h; maximal cell density, 2.9 × 106
cells/well [Fig. 7B]). In addition, the anchorage-independent growth
ability of NU-GC-3 was significantly enhanced by EBV infection (Table
2). Repeated tests showed that such
EBV-dependent growth differences in NU-GC-3 were retained for at least
6 months after isolation of those clones.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
(A) Detection of EBNAs (top blot) and LMP1 (bottom blot)
in EBV-converted NU-GC-3 cells by immunoblotting. (B) EBV
induced-growth alteration of NU-GC-3 cells. Growth curves of
EBV-infected (solid circles) and Neor-transfected NU-GC-3
(open circles) clones in medium containing 10% FCS are shown. The
assay was carried out in six-well culture plates. Data are expressed as
described in the legend to Fig. 4C.
|
|
 |
DISCUSSION |
We demonstrated here that EBV is capable of infecting and
immortalizing primary epithelial cells, although only in one culture. Moreover, we found that EBV could convert already established carcinoma
cells into ones with more malignant phenotypes. In such EBV-induced
events, the patterns of EBV expression in both primary-culture cells
and carcinoma cells were identical to those of EBV-associated gastric
carcinoma (13) and LMP1-negative NPC (47), i.e.,
so-called type I latency characterized by the absence of EBNA2 (due to
Qp usage) and LMP1 expression (28). Although the effects of
EBV on inducing epithelial cell growth have been suggested to be caused by LMP1 (5, 7, 8, 21), we could not detect LMP1 expression in these cells even by a very sensitive RT-PCR assay. Our results indicated that EBV genes other than LMP1 exerts the effects on epithelial cell growth.
We have recently provided evidence that EBV is necessary for the
malignant phenotype of the Burkitt's lymphoma-derived Akata cell line
by comparing EBV-positive and -negative Akata cell clones (36) and by reinfecting EBV-negative cell clones
(15). Both EBV-positive and EBV-reinfected Akata cells
represent type I latency. The present results strongly suggest that the
persistence of EBV with type I latency contributes to the malignant
growth phenotype not only of lymphoid neoplasias but also of
epithelioid neoplasias. Several studies have shown the potential roles
of EBNA1 and EBERs in oncogenic or growth-promoting effects (3,
16, 42). Although LMP2A has not yet been demonstrated to act as a
direct effector of cell growth, it may associate with the maintenance
of EBV latency through phosphorylation by src family
tyrosine kinases and a mitogen-activated protein kinase (20,
24).
Among 21 primary epithelial cultures examined, EBNA was detected in a
small fraction of cells in 3 cultures only. As we reported recently
(14), cocultivation of primary-culture cells with
EBV-producing Akata cells revealed a 10-fold-higher efficiency of EBV
infection than that with cell-free virus preparations, even though
gastric epithelium seems to be relatively resistant to EBV infection. It is not known whether there is a specific cell type susceptible to
EBV or whether the state of cell differentiation influences the
susceptibility to EBV.
Moreover, our results suggest that EBV alone is not sufficient to
immortalize primary epithelial cells, because we could obtain immortalized cells from only one culture even though EBV infection was
detected in three cultures. PGE-5 cells seemed to have already acquired
intrinsic growth potential, since they could be propagated for up to 30 passages without EBV infection, in contrast to other primary-culture
cells, which became extinct within 1 month. A point mutation in intron
5 similar to that found in PGE-5 cells was also found in a sample from
a patient with gastric epithelial dysplasia (32). Although
the relationship between intron mutation and p53 accumulation has not
been clarified, loss of functions of the p53 tumor suppressor gene may
confer basic growth potential to PGE-5 cells, and addition of EBV
function leads to immortalization. A recent study documented frequent
p53 accumulation in potentially premalignant lesions of the
nasopharyngeal epithelium as well as in fully malignant cells,
suggesting that p53 overexpression may precede EBV infection in an
early stage of NPC development (10). Accumulation of p53
protein was reported to occur in about 60 to 70% of patients with
gastric carcinoma and precancerous lesions (adenoma and dysplasia)
(4, 32), and, more interestingly, in about 40% of those
with the precancerous intestinal metaplasia of the gastric mucosa
(23, 32). A relatively small-scale survey showed that the
p53 gene is overexpressed in more than half of the patients with
EBV-positive gastric carcinoma tested (9). Thus, p53
alterations may be an additional event required for the genesis of
EBV-associated epithelial malignancies, by way of the auxiliary
functions for cell cycling (2, 17) or inhibitory effects of
apoptotic epithelial cell death (45).
To our knowledge, our research has demonstrated for the first time that
EBV infection showing type I latency is functionally associated with
epithelial growth promotion. Further studies are necessary to determine
which genes expressed in type I latency play this role. In this regard,
since the two kinds of cells used in this study, PGE-5 and NU-GC-3,
were sensitive to the EBV-induced growth promotion, they will serve as
a useful indicator to identify the viral gene(s) responsible for such activities.
 |
ACKNOWLEDGMENTS |
We thank M. Asaka and S. Todo for providing valuable tissue samples.
This work was supported in part by grants-in-aid from the Ministry of
Education, Science, Sports, and Culture, Japan, and from the Vehicle
Racing Commemorative Foundation and the Suhara Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Virology, Cancer Institute, Hokkaido University School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan. Phone: 81-11-706-5071. Fax: 81-11-717-1128. E-mail: kentaka{at}med.hokudai.ac.jp.
 |
REFERENCES |
| 1.
|
Akiyama, S.,
H. Amo,
T. Watanabe,
M. Matsuyama,
J. Sakamoto,
M. Imaizumi,
H. Ichihashi,
T. Kondo, and H. Takagi.
1988.
Characteristics of three human gastric cancer cell lines, NU-GC-2, NU-GC-3 and NU-GC-4.
Jpn. J. Surg.
18:438-446[Medline].
|
| 2.
|
Baker, S. J.,
S. Markowitz, and E. R. Fearson.
1990.
Suppression of human colorectal cell growth by wild-type p53.
Science
249:912-915[Abstract/Free Full Text].
|
| 3.
|
Clarke, P. A.,
M. Schwemmle,
J. Schickinger,
K. Hilse, and M. J. Clemens.
1992.
Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI.
Nucleic Acids Res.
19:243-248[Abstract/Free Full Text].
|
| 4.
|
Craanen, M. E.,
P. Blok,
W. Dekker,
G. J. Offerhaus, and G. N. Tygat.
1995.
Chronology of p53 protein accumulation in gastric carcinogenesis.
Gut
36:848-852[Abstract/Free Full Text].
|
| 5.
|
Dawson, C. W.,
A. B. Rickinson, and L. S. Young.
1990.
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation.
Nature
344:777-780[Medline].
|
| 6.
|
Dimery, I. W.,
J. S. Lee,
M. Blick,
G. Pearson,
G. Spitzer, and W. K. Hong.
1988.
Association of the Epstein-Barr virus with lymphoepithelioma of the thymus.
Cancer
61:2475-2480[Medline].
|
| 7.
|
Fahraeus, R.,
L. Rymo,
J. S. Rhim, and G. Klein.
1990.
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus.
Nature
345:447-449[Medline].
|
| 8.
|
Fries, K. L.,
W. E. Miller, and N. Raab-Traub.
1996.
Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.
J. Virol.
70:8653-8659[Abstract].
|
| 9.
|
Gulley, M. L.,
D. R. Pulitzer,
P. A. Eagan, and B. G. Schneider.
1996.
Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation.
Hum. Pathol.
27:20-27[Medline].
|
| 10.
|
Gulley, M. L.,
M. P. Burton,
D. C. Allred,
J. M. Nicholls,
M. B. Amin,
J. Y. Ro, and B. G. Schneider.
1998.
Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma.
Hum. Pathol.
29:252-259[Medline].
|
| 11.
|
Harn, H. J.,
L. I. Ho,
W. H. Chung,
J. J. Lin,
H. S. Lee, and W. H. Lee.
1995.
Epstein-Barr virus-associated typical gastric carcinoma detected by in situ hybridization and polymerase chain reaction.
J. Clin. Gastroenterol.
20:253-254[Medline].
|
| 12.
|
Hurley, E. A.,
S. Agger,
J. A. MacNeil,
J. B. Laurence,
A. Calender,
G. Lenoir, and D. A. Thorley-Lawson.
1991.
When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates.
J. Virol.
65:1245-1254[Abstract/Free Full Text].
|
| 13.
|
Imai, S.,
S. Koizumi,
M. Sugiura,
M. Tokunaga,
Y. Uemura,
N. Yamamoto,
S. Tanaka,
E. Sato, and T. Osato.
1994.
Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein.
Proc. Natl. Acad. Sci. USA
91:9131-9135[Abstract/Free Full Text].
|
| 14.
|
Imai, S.,
J. Nishikawa, and K. Takada.
1998.
Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells.
J. Virol.
72:4371-4378[Abstract/Free Full Text].
|
| 15.
|
Komano, J.,
M. Sugiura, and K. Takada.
1998.
Epstein-Barr virus contributes to the malignant phenotype and apotosis resistance in Burkitt's lymphoma cell line Akata.
J. Virol.
72:9150-9156[Abstract/Free Full Text].
|
| 16.
|
Koromilas, A. E.,
S. Roy,
G. N. Barber,
M. G. Katze, and N. Sonenberg.
1992.
Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase.
Science
257:1685-1689[Abstract/Free Full Text].
|
| 17.
|
Kuerbitz, S. J.,
B. S. Plunkett,
W. V. Walsh, and M. B. Kastan.
1992.
Wild-type p53 is a cell cycle check point determinant following irradiation.
Proc. Natl. Acad. Sci. USA
89:7491-7495[Abstract/Free Full Text].
|
| 18.
|
Leoncini, L.,
C. Vindigni,
T. Megha,
I. Funto,
L. Pacenti,
M. Musaro,
A. Renieri,
M. Seri,
J. Anagnostopoulos, and P. Tosi.
1993.
Epstein-Barr virus and gastric cancer, data and unanswered questions.
Int. J. Cancer
53:898-901[Medline].
|
| 19.
|
Matsuo, T.,
M. Heller,
L. Petti,
E. O'Shiro, and E. Kieff.
1984.
Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA.
Science
226:1322-1325[Abstract/Free Full Text].
|
| 20.
|
Miller, C. L.,
A. L. Burkhardt,
J. H. Lee,
B. Stealey,
R. Longnecker,
J. B. Bolen, and E. Kieff.
1995.
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases.
Immunity
2:155-166[Medline].
|
| 21.
|
Miller, W. E.,
H. S. Earp, and N. Raab-Traub.
1995.
The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor.
J. Virol.
69:4390-4398[Abstract].
|
| 22.
|
Nonkwelo, C.,
J. Skinner,
A. Bell,
A. Rickinson, and J. Sample.
1996.
Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.
J. Virol.
70:623-627[Abstract].
|
| 23.
|
Ochiai, A.,
Y. Yamauchi, and S. Hirohashi.
1996.
p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia.
Int. J. Cancer
69:28-33[Medline].
|
| 24.
|
Panousis, C. G., and D. T. Rowe.
1997.
Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase.
J. Virol.
71:4752-4760[Abstract].
|
| 25.
|
Pearson, G. R.,
B. Vroman,
B. Chase,
T. Sculley,
M. Hummel, and E. Kieff.
1983.
Identification of polypeptide components of the Epstein-Barr virus early antigen complex by using monoclonal antibodies.
J. Virol.
47:193-201[Abstract/Free Full Text].
|
| 26.
|
Raab-Traub, N., and K. Flynn.
1986.
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation.
Cell
47:883-889[Medline].
|
| 27.
|
Rickinson, A. B., and E. Kieff.
1996.
Epstein-Barr virus, p. 2397-2446.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
|
| 28.
|
Rowe, M.,
A. L. Lear,
D. Croom-Carter,
A. H. Davis, and A. B. Rickinson.
1992.
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
J. Virol.
66:122-131[Abstract/Free Full Text].
|
| 29.
|
Saw, D.,
D. H. Lau,
J. H. C. Ho,
J. K. C. Chan, and C. S. Ng.
1986.
Malignant lymphoepithelial lesion of the salivary gland.
Hum. Pathol.
17:914-923[Medline].
|
| 30.
|
Selves, J.,
F. Bibeau,
P. Brousset,
F. Meggetto,
C. Mazerolles,
J. J. Voigt,
B. Pradere,
P. Chiotasso, and G. Delsol.
1996.
Epstein-Barr virus latent and replicative gene expression in gastric carcinoma.
Histopathology
28:121-127[Medline].
|
| 31.
|
Schaefer, B. C.,
J. L. Strominger, and S. H. Speck.
1995.
Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.
Proc. Natl. Acad. Sci. USA
92:10565-10569[Abstract/Free Full Text].
|
| 32.
|
Shiao, Y. H.,
M. Rugge,
P. Correa,
H. P. Lehmann, and W. D. Scheer.
1994.
p53 alteration in gastric precancerous lesions.
Am. J. Pathol.
144:511-517[Abstract].
|
| 33.
|
Shibata, D.,
M. Tokunaga,
Y. Uemura,
E. Sato,
S. Tanaka, and L. M. Weiss.
1991.
Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma.
Am. J. Pathol.
139:469-474[Abstract].
|
| 34.
|
Shibata, D., and L. M. Weiss.
1992.
Epstein-Barr virus-associated gastric adenocarcinoma.
Am. J. Pathol.
140:769-774[Abstract].
|
| 35.
|
Shimizu, N.,
H. Yoshiyama, and K. Takada.
1996.
Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.
J. Virol.
70:7260-7263[Abstract/Free Full Text].
|
| 36.
|
Shimizu, N.,
A. Tanabe-Tochikura,
Y. Kuroiwa, and K. Takada.
1994.
Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.
J. Virol.
68:6069-6073[Abstract/Free Full Text].
|
| 37.
|
Sugiura, M.,
S. Imai,
M. Tokunaga,
S. Koizumi,
M. Uchizawa,
K. Okamoto, and T. Osato.
1996.
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.
Br. J. Cancer
74:625-631[Medline].
|
| 38.
|
Takada, K., and Y. Ono.
1989.
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.
J. Virol.
63:445-449[Abstract/Free Full Text].
|
| 39.
|
Thorley-Lawson, D. A., and K. Geilinger.
1980.
Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
Proc. Natl. Acad. Sci. USA
77:5307-5311[Abstract/Free Full Text].
|
| 40.
|
Weiss, L. M.,
Y. Y. Chen,
X. F. Liu, and D. Shibata.
1991.
Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study.
Am. J. Pathol.
139:1259-1265[Abstract].
|
| 41.
|
Wilson, J. B.,
W. Weinberg,
R. Johnson,
S. Yuspa, and A. J. Levine.
1990.
Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6.
Cell
61:1315-1327[Medline].
|
| 42.
|
Wilson, J. B., and A. J. Levine.
1992.
The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice.
Curr. Top. Microbiol. Immunol.
182:375-384[Medline].
|
| 43.
|
Yoshiyama, H.,
N. Shimizu, and K. Takada.
1995.
Persistent Epstein-Barr virus infection in a human T-cell line: unique program of latent viral expression.
EMBO J.
14:3706-3711[Medline].
|
| 44.
|
Yoshiyama, H.,
S. Imai,
N. Shimizu, and K. Takada.
1997.
Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21.
J. Virol.
71:5688-5691[Abstract].
|
| 45.
|
Yonish-Rouach, E.,
D. Resnitzky,
J. Lotem,
L. Sachs,
A. Kimchi, and M. Oren.
1991.
Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6.
Nature
353:345-347.
|
| 46.
|
Young, L.,
C. Alfieri,
K. Hennessy,
H. Evans,
C. O'Hara,
K. C. Anderson,
J. Ritz,
R. S. Shapiro,
A. Rickinson,
E. Kieff, and J. I. Cohen.
1989.
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
N. Engl. J. Med.
321:1080-1085[Abstract].
|
| 47.
|
Young, L. S.,
C. W. Dawson,
D. Clark,
H. Rupani,
P. Busson,
T. Tursz,
A. Johnson, and A. B. Rickinson.
1988.
Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
J. Gen. Virol.
69:1051-1065[Abstract/Free Full Text].
|
Journal of Virology, February 1999, p. 1286-1292, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lin, J.-H., Tsai, C.-H., Chu, J.-S., Chen, J.-Y., Takada, K., Shew, J.-Y.
(2007). Dysregulation of HER2/HER3 Signaling Axis in Epstein-Barr Virus-Infected Breast Carcinoma Cells. J. Virol.
81: 5705-5713
[Abstract]
[Full Text]
-
Allen, M. D., Young, L. S., Dawson, C. W.
(2005). The Epstein-Barr Virus-Encoded LMP2A and LMP2B Proteins Promote Epithelial Cell Spreading and Motility. J. Virol.
79: 1789-1802
[Abstract]
[Full Text]
-
Pegtel, D. M., Middeldorp, J., Thorley-Lawson, D. A.
(2004). Epstein-Barr Virus Infection in Ex Vivo Tonsil Epithelial Cell Cultures of Asymptomatic Carriers. J. Virol.
78: 12613-12624
[Abstract]
[Full Text]
-
Stewart, S., Dawson, C. W., Takada, K., Curnow, J., Moody, C. A., Sixbey, J. W., Young, L. S.
(2004). Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-{kappa}B transcription factor pathway. Proc. Natl. Acad. Sci. USA
101: 15730-15735
[Abstract]
[Full Text]
-
Iwakiri, D., Eizuru, Y., Tokunaga, M., Takada, K.
(2003). Autocrine Growth of Epstein-Barr Virus-Positive Gastric Carcinoma Cells Mediated by an Epstein-Barr Virus-Encoded Small RNA. Cancer Res.
63: 7062-7067
[Abstract]
[Full Text]
-
Lu, J., Chua, H.-H., Chen, S.-Y., Chen, J.-Y., Tsai, C.-H.
(2003). Regulation of Matrix Metalloproteinase-1 by Epstein-Barr Virus Proteins. Cancer Res.
63: 256-262
[Abstract]
[Full Text]
-
Neuhierl, B., Feederle, R., Hammerschmidt, W., Delecluse, H. J.
(2002). Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc. Natl. Acad. Sci. USA
99: 15036-15041
[Abstract]
[Full Text]
-
Vo, Q N, Geradts, J, Gulley, M L, Boudreau, D A, Bravo, J C, Schneider, B G
(2002). Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. J. Clin. Pathol.
55: 669-675
[Abstract]
[Full Text]
-
Chen, S.-Y., Lu, J., Shih, Y.-C., Tsai, C.-H.
(2002). Epstein-Barr Virus Latent Membrane Protein 2A Regulates c-Jun Protein through Extracellular Signal-Regulated Kinase. J. Virol.
76: 9556-9561
[Abstract]
[Full Text]
-
Maruo, S., Yang, L., Takada, K.
(2001). Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J. Gen. Virol.
82: 2373-2383
[Abstract]
[Full Text]
-
Shirakata, M., Imadome, K.-I., Okazaki, K., Hirai, K.
(2001). Activation of TRAF5 and TRAF6 Signal Cascades Negatively Regulates the Latent Replication Origin of Epstein-Barr Virus through p38 Mitogen-Activated Protein Kinase. J. Virol.
75: 5059-5068
[Abstract]
[Full Text]
-
Tierney, R., Kirby, H., Nagra, J., Rickinson, A., Bell, A.
(2000). The Epstein-Barr Virus Promoter Initiating B-Cell Transformation Is Activated by RFX Proteins and the B-Cell-Specific Activator Protein BSAP/Pax5. J. Virol.
74: 10458-10467
[Abstract]
[Full Text]
-
Yang, L., Maruo, S., Takada, K.
(2000). CD21-Mediated Entry and Stable Infection by Epstein-Barr Virus in Canine and Rat Cells. J. Virol.
74: 10745-10751
[Abstract]
[Full Text]
-
Takada, K
(2000). Epstein-Barr virus and gastric carcinoma. Mol. Pathol.
53: 255-261
[Abstract]
[Full Text]
-
Decaussin, G., Sbih-Lammali, F., Mireille de Turenne-Tessier, , Bouguermouh, A., Ooka, T.
(2000). Expression of BARF1 Gene Encoded by Epstein-Barr Virus in Nasopharyngeal Carcinoma Biopsies. Cancer Res.
60: 5584-5588
[Abstract]
[Full Text]
-
Lu, J., Chen, S.-Y., Chua, H.-H., Liu, Y.-S., Huang, Y.-T., Chang, Y., Chen, J.-Y., Sheen, T.-S., Tsai, C.-H.
(2000). Upregulation of Tyrosine Kinase TKT by the Epstein-Barr Virus Transactivator Zta. J. Virol.
74: 7391-7399
[Abstract]
[Full Text]